TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
Crossref DOI link: https://doi.org/10.1186/1471-2407-14-360
Published Online: 2014-05-22
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jørgensen, Charlotte Levin Tykjær
Bjerre, Christina
Ejlertsen, Bent
Bjerre, Karsten D
Balslev, Eva
Bartels, Annette
Brünner, Nils
Nielsen, Dorte L
License valid from 2014-05-22